Abstract:Therapeutic Advances in Drug Safety, Volume 14, Issue , January-December 2023. Purpose:Unpredictable drug efficacy and safety of combined antiepileptic therapy is a major challenge during pharmacotherapy decisions in everyday clinical practice. The aim of this study was to describe the pharmacokinetics of valproic acid (VA), lamotrigine (LTG), and levetiracetam (LEV) in a pediatric population using nonlinear mixed-effect modeling, while machine learning (ML) algorithms were applied to identify any relationships among the plasma levels of the three medications and patients' characteristics, as well as to develop a predictive model for epileptic seizures.Methods:The study included 71 pediatric patients of both genders, aged 2–18 years, on combined antiepileptic therapy. Population pharmacokinetic (PopPK) models were developed separately for VA, LTG, and LEV. Based on the estimated pharmacokinetic parameters and the patients' characteristics, three ML approaches were applied (principal component analysis, factor analysis of mixed data, and random forest). PopPK models and ML models were developed, allowing for greater insight into the treatment of children on antiepileptic treatment.Results:Results from the PopPK model showed that the kinetics of LEV, LTG, and VA were best described by a one compartment model with first-order absorption and elimination kinetics. Reliance on random forest model is a compelling vision that shows high prediction ability for all cases. The main factor that can affect antiepileptic activity is antiepileptic drug levels, followed by body weight, while gender is irrelevant. According to our study, children's age is positively associated with LTG levels, negatively with LEV and without the influence of VA.Conclusion:The application of PopPK and ML models may be useful to improve epilepsy management in vulnerable pediatric population during the period of growth and development.Plain language summaryPharmacokinetics and machine learning in epilepsy Nowadays, combined antiepileptic therapy is the best option for a number of pediatric patients. Furthermore, there are no standard procedures in the therapy management of this complex treatment. Besides therapeutic monitoring, the population pharmacokinetic (PopPK) approach and machine learning (ML) are useful sources of information regarding the optimization of therapy. The aim of this study was to describe the pharmacokinetics of valproic acid (VA), lamotrigine (LTG), and levetiracetam (LEV) in a pediatric population using nonlinear mixed-effect modeling, while ML algorithms were applied to identify any relationships among the plasma levels of the three medications and patients' characteristics. The study included 71 pediatric patients of both genders, aged 2–18 years, on combined antiepileptic therapy. Population pharmacokinetic (PopPK) models were developed separately for VA, LTG, and LEV. Based on the estimated pharmacokinetic parameters and the patients' characteristics, three ML approaches were applied (principal component analysis, factor analysis of mixed data, and random forest). According to our study, children's age is positively associated with LTG levels, negatively with LEV and without influence from VA. However, the gender of patients has no influence on drug plasma concentration. Findings demonstrated that the application of PopPK and ML models may be useful to improve epilepsy management in vulnerable pediatric population during the period of growth and development.

Sources of pharmacokinetic and pharmacodynamic variability and clinical pharmacology studies of antiseizure medications in the pediatric population

Trends of Anti-Seizure Medication Use in Pediatric Patients in Six Cities in China from 2013 to 2018

Pharmacokinetic considerations for anti-epileptic drugs in children

Pharmacokinetic Considerations in the Treatment of Childhood Epilepsy

New Pharmacological Therapies in the Treatment of Epilepsy in the Pediatric Population

Pharmacokinetics and Drug Interaction of Antiepileptic Drugs in Children and Adolescents

Anti-seizure Medications: Challenges and Opportunities

Clinical development of antiepileptic drugs for children

Pragmatic modeling supports current dosing guidelines for carbamazepine and valproic acid for the treatment of epilepsy in children

Pharmacology and Therapeutic Aspects of Antiepileptic Drugs in Pediatrics

Optimizing epilepsy treatment in children, adults and elderly: clinical perspectives

Population pharmacokinetics and dosing optimization of perampanel in children with epilepsy: A real‐world study

Extrapolation of Efficacy from Adults to Pediatric Patients of Drugs for Treatment of Partial Onset Seizures: A Regulatory Perspective

Application of Physiologically Based Pharmacokinetic Modeling to Characterize the Effects of Age and Obesity on the Disposition of Levetiracetam in the Pediatric Population

Safety and tolerability profile of new antiepileptic drug treatment in children with epilepsy

Advances in the individualized treatment of novel antiepileptic drugs for children

Epilepsy: expert opinion on emerging drugs in phase 2/3 clinical trials

Progress of New Antiepileptic Drugs in the Treatment of Epilepsy in Children

Evaluation of drug safety in pediatric epileptic patients: A prospective interventional study with clinical pharmacist intervention at a tertiary care teaching hospital

Joint use of population pharmacokinetics and machine learning for optimizing antiepileptic treatment in pediatric population

Population pharmacokinetics of valproic acid in children with epilepsy: Implications for dose tailoring when switching from oral syrup to sustained‐release tablets